Axonics logo

AxonicsNASDAQ: AXNX

Profile

Sector:

Healthcare

Country:

United States

IPO:

31 October 2018

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.59 B
-6%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
84%vs. sector
-56%vs. 3y high
73%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:46:57 GMT
$70.22-$0.05(-0.07%)

Dividend

No data over the past 3 years
$114.56 M$113.50 M
$114.56 M$6.90 M

Analysts recommendations

Institutional Ownership

AXNX Latest News

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
zacks.com27 September 2024 Sentiment: POSITIVE

AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
businesswire.com26 September 2024 Sentiment: POSITIVE

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.

Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
zacks.com25 September 2024 Sentiment: POSITIVE

AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.

Axonics Prevails in Patent Infringement Lawsuit with Medtronic
businesswire.com18 September 2024 Sentiment: POSITIVE

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellect.

Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
zacks.com01 August 2024 Sentiment: POSITIVE

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago.

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Zacks Investment Research29 March 2024 Sentiment: POSITIVE

Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Zacks Investment Research15 March 2024 Sentiment: POSITIVE

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research28 February 2024 Sentiment: POSITIVE

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.

4 Stocks Backed by High Efficiency to Enrich Your Portfolio
Zacks Investment Research31 January 2024 Sentiment: POSITIVE

Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.

Why Axonics Stock Soared Today
The Motley Fool08 January 2024 Sentiment: POSITIVE

Axonics has agreed to be acquired by Boston Scientific for $71 per share in cash. Assuming the deal receives the approval of shareholders and regulators, it should close in the first half of 2024.

  • 1(current)

What type of business is Axonics?

Axonics, Inc., a medical technology company, is engaged in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary incontinence and frequency of urination, as well as fecal incontinence and non-obstructive urinary retention. Its patented rechargeable SNM system (r-SNM) delivers weak electrical impulses to the target sacral nerve to restore normal communication with the brain and from it, in order to reduce symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent for the treatment of stress urinary incontinence in women. The company was previously known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was registered in 2012, with its headquarters located in Irvine, California.

What sector is Axonics in?

Axonics is in the Healthcare sector

What industry is Axonics in?

Axonics is in the Medical Devices industry

What country is Axonics from?

Axonics is headquartered in United States

When did Axonics go public?

Axonics initial public offering (IPO) was on 31 October 2018

What is Axonics website?

https://www.axonics.com

Is Axonics in the S&P 500?

No, Axonics is not included in the S&P 500 index

Is Axonics in the NASDAQ 100?

No, Axonics is not included in the NASDAQ 100 index

Is Axonics in the Dow Jones?

No, Axonics is not included in the Dow Jones index

When was Axonics the previous earnings report?

No data

When does Axonics earnings report?

The next expected earnings date for Axonics is 06 November 2024